Last updated: 11/07/2018 06:18:20
WE808086 Balanced Cohort Study of Thiazolidinediones (TZDs) and other Anti-diabetic Therapies and Coronary Heart Disease Events
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: WE808086 Balanced Cohort Study of Thiazolidinediones (TZDs) and other Anti-diabetic Therapies and Coronary Heart Disease Events
Trial description: WE808086 Balanced Cohort Study of Thiazolidinediones (TZDs) and other Anti-diabetic Therapies and Coronary Heart Disease Events
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger, JD. The Risk of Coronary Heart Disease in Type 2 Diabetic Patients Exposed to Thiazolidinediones Compared to Metformin and Sulfonylurea Therapy. Pharmacoepidemiology and Drug Safety 2007;16(5): 504-512
Medical condition
Infarction, Myocardial
Product
glimepiride, metformin, rosiglitazone, rosiglitazone/glimepiride, rosiglitazone/metformin
Collaborators
Not applicable
Study date(s)
July 2003 to August 2004
Type
Not applicable
Phase
Not applicable
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2004-09-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website